25 XP   0   0   10

Zealand Pharma A/S
Buy, Hold or Sell?

Let's analyse Zealand Pharma A/S together

PenkeI guess you are interested in Zealand Pharma A/S. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Zealand Pharma A/S. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Zealand Pharma A/S

I send you an email if I find something interesting about Zealand Pharma A/S.

Quick analysis of Zealand Pharma A/S (30 sec.)










What can you expect buying and holding a share of Zealand Pharma A/S? (30 sec.)

How much money do you get?

How much money do you get?
kr0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
kr25.59
Expected worth in 1 year
kr38.08
How sure are you?
32.5%

+ What do you gain per year?

Total Gains per Share
kr12.48
Return On Investment
1.8%

For what price can you sell your share?

Current Price per Share
kr681.50
Expected price per share
kr502.00 - kr749.00
How sure are you?
50%

1. Valuation of Zealand Pharma A/S (5 min.)




Live pricePrice per Share (EOD)

kr681.50

Intrinsic Value Per Share

kr-84.69 - kr223.97

Total Value Per Share

kr-59.09 - kr249.56

2. Growth of Zealand Pharma A/S (5 min.)




Is Zealand Pharma A/S growing?

Current yearPrevious yearGrowGrow %
How rich?$230.9m$86.8m$123.7m58.7%

How much money is Zealand Pharma A/S making?

Current yearPrevious yearGrowGrow %
Making money-$25.5m-$39.3m$13.8m54.4%
Net Profit Margin-1,401.3%-1,103.6%--

How much money comes from the company's main activities?

3. Financial Health of Zealand Pharma A/S (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#232 / 1031

Most Revenue
#271 / 1031

Most Profit
#792 / 1031

Most Efficient
#842 / 1031

What can you expect buying and holding a share of Zealand Pharma A/S? (5 min.)

Welcome investor! Zealand Pharma A/S's management wants to use your money to grow the business. In return you get a share of Zealand Pharma A/S.

What can you expect buying and holding a share of Zealand Pharma A/S?

First you should know what it really means to hold a share of Zealand Pharma A/S. And how you can make/lose money.

Speculation

The Price per Share of Zealand Pharma A/S is kr681.50. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Zealand Pharma A/S.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Zealand Pharma A/S, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is kr25.59. Based on the TTM, the Book Value Change Per Share is kr3.12 per quarter. Based on the YOY, the Book Value Change Per Share is kr-0.45 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is kr0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Zealand Pharma A/S.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 kr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Share
Usd Eps-0.62-0.1%-0.41-0.1%-0.70-0.1%-0.51-0.1%-0.250.0%
Usd Book Value Change Per Share-0.52-0.1%0.450.1%-0.070.0%0.060.0%0.070.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.52-0.1%0.450.1%-0.070.0%0.060.0%0.070.0%
Usd Price Per Share54.11-41.27-20.74-29.15-22.11-
Price to Earnings Ratio-21.93-3.27--9.40--12.49--12.50-
Price-to-Total Gains Ratio-103.71-7.50--27.04--58.51--106.87-
Price to Book Ratio14.58-13.43-16.36-11.54-19.04-
Price-to-Total Gains Ratio-103.71-7.50--27.04--58.51--106.87-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share98.8175
Number of shares10
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.450.06
Usd Total Gains Per Share0.450.06
Gains per Quarter (10 shares)4.530.56
Gains per Year (10 shares)18.102.22
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1018802-8
20362604-6
30544407-4
40726209-2
5091800110
60109980132
701271160164
801451340186
901631520208
10018117002210

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%1.011.00.08.3%1.019.00.05.0%6.034.00.015.0%10.045.00.018.2%
Book Value Change Per Share2.02.00.050.0%4.08.00.033.3%6.014.00.030.0%13.027.00.032.5%17.036.02.030.9%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.055.00.0%
Total Gains per Share2.02.00.050.0%4.08.00.033.3%6.014.00.030.0%13.027.00.032.5%17.036.02.030.9%

Fundamentals of Zealand Pharma A/S

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.

Fundamental data was last updated by Penke on 2024-03-22 13:13:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is cheap.
Based on how much money comes from the company's main activities, the company is cheap.

1.1. Profitability of Zealand Pharma A/S.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Zealand Pharma A/S earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compare Zealand Pharma A/S to the Biotechnology industry mean.
  • A Net Profit Margin of -1,139.4% means that kr-11.39 for each kr1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Zealand Pharma A/S:

  • The MRQ is -1,139.4%. The company is making a huge loss. -2
  • The TTM is -1,401.3%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-1,139.4%TTM-1,401.3%+261.9%
TTM-1,401.3%YOY-1,103.6%-297.8%
TTM-1,401.3%5Y-878.8%-522.5%
5Y-878.8%10Y-731.6%-147.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,139.4%-159.2%-980.2%
TTM-1,401.3%-202.3%-1,199.0%
YOY-1,103.6%-263.0%-840.6%
5Y-878.8%-452.4%-426.4%
10Y-731.6%-589.0%-142.6%
1.1.2. Return on Assets

Shows how efficient Zealand Pharma A/S is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Zealand Pharma A/S to the Biotechnology industry mean.
  • -13.4% Return on Assets means that Zealand Pharma A/S generated kr-0.13 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Zealand Pharma A/S:

  • The MRQ is -13.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -10.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-13.4%TTM-10.0%-3.4%
TTM-10.0%YOY-19.8%+9.8%
TTM-10.0%5Y-12.8%+2.8%
5Y-12.8%10Y-9.0%-3.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-13.4%-12.5%-0.9%
TTM-10.0%-12.2%+2.2%
YOY-19.8%-11.2%-8.6%
5Y-12.8%-13.3%+0.5%
10Y-9.0%-14.6%+5.6%
1.1.3. Return on Equity

Shows how efficient Zealand Pharma A/S is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Zealand Pharma A/S to the Biotechnology industry mean.
  • -16.6% Return on Equity means Zealand Pharma A/S generated kr-0.17 for each kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Zealand Pharma A/S:

  • The MRQ is -16.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -14.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-16.6%TTM-14.9%-1.7%
TTM-14.9%YOY-48.0%+33.0%
TTM-14.9%5Y-22.4%+7.5%
5Y-22.4%10Y-19.2%-3.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-16.6%-16.0%-0.6%
TTM-14.9%-15.8%+0.9%
YOY-48.0%-13.9%-34.1%
5Y-22.4%-18.2%-4.2%
10Y-19.2%-19.1%-0.1%

1.2. Operating Efficiency of Zealand Pharma A/S.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Zealand Pharma A/S is operating .

  • Measures how much profit Zealand Pharma A/S makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Zealand Pharma A/S to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated kr0.00  for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Zealand Pharma A/S:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-778.7%+778.7%
TTM-778.7%YOY-1,051.6%+272.8%
TTM-778.7%5Y-749.9%-28.9%
5Y-749.9%10Y-631.2%-118.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--299.5%+299.5%
TTM-778.7%-208.5%-570.2%
YOY-1,051.6%-280.2%-771.4%
5Y-749.9%-459.9%-290.0%
10Y-631.2%-596.9%-34.3%
1.2.2. Operating Ratio

Measures how efficient Zealand Pharma A/S is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 12.13 means that the operating costs are kr12.13 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of Zealand Pharma A/S:

  • The MRQ is 12.134. The company is inefficient in keeping operating costs low. -1
  • The TTM is 11.793. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ12.134TTM11.793+0.341
TTM11.793YOY10.262+1.530
TTM11.7935Y8.799+2.994
5Y8.79910Y7.666+1.133
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ12.1342.817+9.317
TTM11.7933.181+8.612
YOY10.2623.609+6.653
5Y8.7995.554+3.245
10Y7.6667.396+0.270

1.3. Liquidity of Zealand Pharma A/S.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Zealand Pharma A/S is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 6.25 means the company has kr6.25 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of Zealand Pharma A/S:

  • The MRQ is 6.254. The company is very able to pay all its short-term debts. +2
  • The TTM is 7.645. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.254TTM7.645-1.391
TTM7.645YOY4.760+2.885
TTM7.6455Y5.611+2.034
5Y5.61110Y6.973-1.361
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.2543.987+2.267
TTM7.6454.440+3.205
YOY4.7605.569-0.809
5Y5.6116.158-0.547
10Y6.9736.492+0.481
1.3.2. Quick Ratio

Measures if Zealand Pharma A/S is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Zealand Pharma A/S to the Biotechnology industry mean.
  • A Quick Ratio of 4.59 means the company can pay off kr4.59 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Zealand Pharma A/S:

  • The MRQ is 4.590. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 8.711. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.590TTM8.711-4.122
TTM8.711YOY4.365+4.347
TTM8.7115Y6.198+2.513
5Y6.19810Y7.199-1.001
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.5903.653+0.937
TTM8.7114.158+4.553
YOY4.3655.515-1.150
5Y6.1986.012+0.186
10Y7.1996.206+0.993

1.4. Solvency of Zealand Pharma A/S.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Zealand Pharma A/S assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Zealand Pharma A/S to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.20 means that Zealand Pharma A/S assets are financed with 19.6% credit (debt) and the remaining percentage (100% - 19.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Zealand Pharma A/S:

  • The MRQ is 0.196. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.254. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.196TTM0.254-0.058
TTM0.254YOY0.587-0.333
TTM0.2545Y0.328-0.075
5Y0.32810Y0.380-0.052
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1960.336-0.140
TTM0.2540.330-0.076
YOY0.5870.267+0.320
5Y0.3280.367-0.039
10Y0.3800.378+0.002
1.4.2. Debt to Equity Ratio

Measures if Zealand Pharma A/S is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Zealand Pharma A/S to the Biotechnology industry mean.
  • A Debt to Equity ratio of 24.3% means that company has kr0.24 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Zealand Pharma A/S:

  • The MRQ is 0.243. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.405. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.243TTM0.405-0.161
TTM0.405YOY1.486-1.081
TTM0.4055Y0.619-0.214
5Y0.61910Y0.862-0.243
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2430.376-0.133
TTM0.4050.398+0.007
YOY1.4860.334+1.152
5Y0.6190.431+0.188
10Y0.8620.476+0.386

2. Market Valuation of Zealand Pharma A/S

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every kr1 in earnings Zealand Pharma A/S generates.

  • Above 15 is considered overpriced but always compare Zealand Pharma A/S to the Biotechnology industry mean.
  • A PE ratio of -21.93 means the investor is paying kr-21.93 for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Zealand Pharma A/S:

  • The EOD is -40.052. Based on the earnings, the company is expensive. -2
  • The MRQ is -21.933. Based on the earnings, the company is expensive. -2
  • The TTM is 3.267. Based on the earnings, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD-40.052MRQ-21.933-18.119
MRQ-21.933TTM3.267-25.200
TTM3.267YOY-9.403+12.670
TTM3.2675Y-12.488+15.755
5Y-12.48810Y-12.497+0.009
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-40.052-2.697-37.355
MRQ-21.933-2.422-19.511
TTM3.267-2.709+5.976
YOY-9.403-4.116-5.287
5Y-12.488-6.257-6.231
10Y-12.497-6.478-6.019
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Zealand Pharma A/S:

  • The EOD is 215.839. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is 118.197. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 10.271. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD215.839MRQ118.197+97.642
MRQ118.197TTM10.271+107.926
TTM10.271YOY-11.008+21.279
TTM10.2715Y-7.466+17.737
5Y-7.46610Y118.812-126.278
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD215.839-3.344+219.183
MRQ118.197-2.939+121.136
TTM10.271-3.486+13.757
YOY-11.008-5.592-5.416
5Y-7.466-8.464+0.998
10Y118.812-8.872+127.684
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Zealand Pharma A/S is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 14.58 means the investor is paying kr14.58 for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of Zealand Pharma A/S:

  • The EOD is 26.629. Based on the equity, the company is expensive. -2
  • The MRQ is 14.582. Based on the equity, the company is expensive. -2
  • The TTM is 13.432. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD26.629MRQ14.582+12.046
MRQ14.582TTM13.432+1.150
TTM13.432YOY16.364-2.932
TTM13.4325Y11.545+1.887
5Y11.54510Y19.044-7.499
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD26.6292.198+24.431
MRQ14.5822.042+12.540
TTM13.4322.121+11.311
YOY16.3642.907+13.457
5Y11.5453.682+7.863
10Y19.0444.114+14.930
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Zealand Pharma A/S compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---3.5983.121-215%-0.449-88%0.383-1040%0.513-802%
Book Value Per Share--25.59323.339+10%9.628+166%19.165+34%12.592+103%
Current Ratio--6.2547.645-18%4.760+31%5.611+11%6.973-10%
Debt To Asset Ratio--0.1960.254-23%0.587-67%0.328-40%0.380-49%
Debt To Equity Ratio--0.2430.405-40%1.486-84%0.619-61%0.862-72%
Dividend Per Share----0%-0%-0%-0%
Eps---4.254-2.827-34%-4.829+14%-3.489-18%-1.752-59%
Free Cash Flow Per Share--0.789-1.805+329%-3.832+585%-3.040+485%-1.917+343%
Free Cash Flow To Equity Per Share--0.7891.799-56%-1.472+287%0.377+110%0.013+6062%
Gross Profit Margin--1.0001.012-1%1.085-8%1.194-16%1.097-9%
Intrinsic Value_10Y_max--223.971--------
Intrinsic Value_10Y_min---84.686--------
Intrinsic Value_1Y_max---3.314--------
Intrinsic Value_1Y_min---13.252--------
Intrinsic Value_3Y_max--9.673--------
Intrinsic Value_3Y_min---35.926--------
Intrinsic Value_5Y_max--46.326--------
Intrinsic Value_5Y_min---54.160--------
Market Cap42414924400.000+45%23227072320.00017712820960.000+31%8903088680.000+161%12512869480.000+86%9488433308.000+145%
Net Profit Margin---11.394-14.013+23%-11.036-3%-8.788-23%-7.316-36%
Operating Margin----7.7870%-10.5160%-7.4990%-6.3120%
Operating Ratio--12.13411.793+3%10.262+18%8.799+38%7.666+58%
Pb Ratio26.629+45%14.58213.432+9%16.364-11%11.545+26%19.044-23%
Pe Ratio-40.052-83%-21.9333.267-771%-9.403-57%-12.488-43%-12.497-43%
Price Per Share681.500+45%373.200284.600+31%143.050+161%201.050+86%152.455+145%
Price To Free Cash Flow Ratio215.839+45%118.19710.271+1051%-11.008+109%-7.466+106%118.812-1%
Price To Total Gains Ratio-189.389-83%-103.7127.502-1482%-27.038-74%-58.512-44%-106.866+3%
Quick Ratio--4.5908.711-47%4.365+5%6.198-26%7.199-36%
Return On Assets---0.134-0.100-25%-0.198+48%-0.128-5%-0.090-32%
Return On Equity---0.166-0.149-10%-0.480+189%-0.224+35%-0.192+16%
Total Gains Per Share---3.5983.121-215%-0.449-88%0.383-1040%0.513-802%
Usd Book Value--230961655.000210623701.250+10%86891068.750+166%172953651.000+34%113632614.000+103%
Usd Book Value Change Per Share---0.5220.453-215%-0.065-88%0.056-1040%0.074-802%
Usd Book Value Per Share--3.7113.384+10%1.396+166%2.779+34%1.826+103%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.617-0.410-34%-0.700+14%-0.506-18%-0.254-59%
Usd Free Cash Flow--7123560.000-16291366.250+329%-34579563.750+585%-27435239.750+485%-17299986.250+343%
Usd Free Cash Flow Per Share--0.114-0.262+329%-0.556+585%-0.441+485%-0.278+343%
Usd Free Cash Flow To Equity Per Share--0.1140.261-56%-0.213+287%0.055+110%0.002+6062%
Usd Market Cap6150164038.000+45%3367925486.4002568359039.200+31%1290947858.600+161%1814366074.600+86%1375822829.660+145%
Usd Price Per Share98.818+45%54.11441.267+31%20.742+161%29.152+86%22.106+145%
Usd Profit---38388750.000-25510538.750-34%-39382507.500+3%-30643270.500-20%-15386410.375-60%
Usd Revenue--3369075.00012426028.750-73%4027012.500-16%8272917.000-59%6872822.375-51%
Usd Total Gains Per Share---0.5220.453-215%-0.065-88%0.056-1040%0.074-802%
 EOD+4 -4MRQTTM+13 -20YOY+22 -115Y+16 -1710Y+18 -15

3.2. Fundamental Score

Let's check the fundamental score of Zealand Pharma A/S based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-40.052
Price to Book Ratio (EOD)Between0-126.629
Net Profit Margin (MRQ)Greater than0-11.394
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than14.590
Current Ratio (MRQ)Greater than16.254
Debt to Asset Ratio (MRQ)Less than10.196
Debt to Equity Ratio (MRQ)Less than10.243
Return on Equity (MRQ)Greater than0.15-0.166
Return on Assets (MRQ)Greater than0.05-0.134
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Zealand Pharma A/S based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5056.503
Ma 20Greater thanMa 50695.275
Ma 50Greater thanMa 100571.588
Ma 100Greater thanMa 200459.804
OpenGreater thanClose698.000
Total5/5 (100.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in DKK. All numbers in thousands.

Summary
Total Assets1,979,993
Total Liabilities387,154
Total Stockholder Equity1,592,839
 As reported
Total Liabilities 387,154
Total Stockholder Equity+ 1,592,839
Total Assets = 1,979,993

Assets

Total Assets1,979,993
Total Current Assets1,779,788
Long-term Assets200,205
Total Current Assets
Cash And Cash Equivalents 449,311
Short-term Investments 1,183,746
Net Receivables 122,359
Inventory 7,935
Total Current Assets  (as reported)1,779,788
Total Current Assets  (calculated)1,763,351
+/- 16,437
Long-term Assets
Property Plant Equipment 149,852
Intangible Assets 12,255
Long-term Assets  (as reported)200,205
Long-term Assets  (calculated)162,107
+/- 38,098

Liabilities & Shareholders' Equity

Total Current Liabilities284,579
Long-term Liabilities102,575
Total Stockholder Equity1,592,839
Total Current Liabilities
Accounts payable 267,924
Total Current Liabilities  (as reported)284,579
Total Current Liabilities  (calculated)267,924
+/- 16,655
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt119,230
Long-term Liabilities  (as reported)102,575
Long-term Liabilities  (calculated)119,230
+/- 16,655
Total Stockholder Equity
Total Stockholder Equity (as reported)1,592,839
Total Stockholder Equity (calculated)0
+/- 1,592,839
Other
Capital Stock58,751
Common Stock Shares Outstanding 58,378
Net Invested Capital 1,592,839
Net Working Capital 1,495,209
Property Plant and Equipment Gross 220,283



Balance Sheet

Currency in DKK. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
> Total Assets 
0
0
0
450,550
408,819
513,417
485,134
469,481
553,361
558,716
564,085
520,983
470,961
432,716
385,834
346,913
381,662
333,097
357,773
596,756
569,235
516,821
535,741
634,688
534,949
477,455
569,706
694,626
474,204
381,069
828,627
737,238
620,497
522,130
1,523,070
1,229,797
1,350,519
1,229,399
1,713,594
1,599,514
1,561,595
2,271,774
2,059,143
1,924,610
2,169,826
1,924,173
1,660,699
2,067,629
1,837,382
1,256,554
1,091,608
1,539,806
1,340,507
2,049,678
2,175,505
1,979,993
1,979,9932,175,5052,049,6781,340,5071,539,8061,091,6081,256,5541,837,3822,067,6291,660,6991,924,1732,169,8261,924,6102,059,1432,271,7741,561,5951,599,5141,713,5941,229,3991,350,5191,229,7971,523,070522,130620,497737,238828,627381,069474,204694,626569,706477,455534,949634,688535,741516,821569,235596,756357,773333,097381,662346,913385,834432,716470,961520,983564,085558,716553,361469,481485,134513,417408,819450,550000
   > Total Current Assets 
0
0
0
437,582
394,026
495,896
464,900
449,114
532,024
536,513
542,989
497,025
447,892
410,262
364,678
324,281
358,792
311,306
336,473
575,436
549,066
496,821
515,777
615,569
517,222
343,651
408,426
373,173
457,261
364,979
811,811
703,193
587,472
488,268
1,495,253
1,178,823
1,293,855
1,176,599
1,577,027
1,427,050
1,369,998
1,945,139
1,703,805
1,245,029
1,828,725
1,575,438
1,313,881
1,721,596
1,581,898
1,000,728
833,885
1,316,352
1,132,772
1,843,870
1,965,934
1,779,788
1,779,7881,965,9341,843,8701,132,7721,316,352833,8851,000,7281,581,8981,721,5961,313,8811,575,4381,828,7251,245,0291,703,8051,945,1391,369,9981,427,0501,577,0271,176,5991,293,8551,178,8231,495,253488,268587,472703,193811,811364,979457,261373,173408,426343,651517,222615,569515,777496,821549,066575,436336,473311,306358,792324,281364,678410,262447,892497,025542,989536,513532,024449,114464,900495,896394,026437,582000
       Cash And Cash Equivalents 
0
0
0
383,305
240,489
296,023
291,836
278,342
326,577
325,725
371,673
358,922
363,343
325,558
332,887
286,178
349,648
297,624
303,812
538,273
523,978
468,607
453,889
418,796
358,763
289,363
224,636
323,330
410,267
302,114
774,654
588,718
487,205
387,022
1,478,612
860,635
962,925
840,802
1,242,871
1,081,060
999,707
1,350,986
1,231,685
860,772
1,307,554
987,777
753,599
1,129,103
1,123,235
553,242
342,584
1,069,234
831,078
327,686
384,441
449,311
449,311384,441327,686831,0781,069,234342,584553,2421,123,2351,129,103753,599987,7771,307,554860,7721,231,6851,350,986999,7071,081,0601,242,871840,802962,925860,6351,478,612387,022487,205588,718774,654302,114410,267323,330224,636289,363358,763418,796453,889468,607523,978538,273303,812297,624349,648286,178332,887325,558363,343358,922371,673325,725326,577278,342291,836296,023240,489383,305000
       Short-term Investments 
0
0
0
52,997
150,631
149,512
150,103
149,358
199,324
199,235
126,654
126,940
77,955
78,022
24,944
24,383
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
75,111
73,891
74,315
0
298,611
300,382
301,292
300,370
299,448
290,935
293,982
296,909
297,345
296,566
295,155
295,379
299,042
0
311,202
0
108,611
170,441
1,364,688
1,197,748
1,183,746
1,183,7461,197,7481,364,688170,441108,6110311,2020299,042295,379295,155296,566297,345296,909293,982290,935299,448300,370301,292300,382298,611074,31573,89175,11100000000000000024,38324,94478,02277,955126,940126,654199,235199,324149,358150,103149,512150,63152,997000
       Net Receivables 
0
0
0
0
0
49,110
20,417
20,334
2,182
1,045
38,986
7,515
1,509
1,232
1,290
10,078
5,568
1,059
26,144
34,954
16,301
16,725
61,888
173,108
34,486
34,177
18,784
22,389
20,364
31,231
24,262
32,111
19,923
19,206
7,862
7,837
6,953
9,584
14,307
15,787
39,589
195,783
60,153
12,695
81,520
146,558
118,075
110,389
92,582
82,724
62,524
115,622
101,321
117,077
351,052
122,359
122,359351,052117,077101,321115,62262,52482,72492,582110,389118,075146,55881,52012,69560,153195,78339,58915,78714,3079,5846,9537,8377,86219,20619,92332,11124,26231,23120,36422,38918,78434,17734,486173,10861,88816,72516,30134,95426,1441,0595,56810,0781,2901,2321,5097,51538,9861,0452,18220,33420,41749,11000000
       Other Current Assets 
0
0
0
1,280
2,906
1,251
2,544
1,080
3,941
10,508
5,676
3,648
5,085
5,450
5,557
10,078
3,576
12,623
6,517
2,209
8,787
11,489
0
23,665
123,973
20,111
135,513
27,454
26,630
31,634
12,895
7,253
6,453
7,725
8,779
11,740
23,595
24,921
19,479
30,755
39,767
34,661
39,896
28,517
48,270
1
30,469
64,626
362,321
0
491,301
137,221
0
0
0
0
0000137,221491,3010362,32164,62630,469148,27028,51739,89634,66139,76730,75519,47924,92123,59511,7408,7797,7256,4537,25312,89531,63426,63027,454135,51320,111123,97323,665011,4898,7872,2096,51712,6233,57610,0785,5575,4505,0853,6485,67610,5083,9411,0802,5441,2512,9061,280000
   > Long-term Assets 
0
0
0
12,968
14,793
17,521
20,234
20,367
21,337
22,203
21,096
23,958
23,069
22,454
21,156
22,632
22,870
21,791
21,300
21,320
20,169
20,000
19,964
19,119
17,727
133,804
161,280
321,453
16,943
16,090
16,816
34,045
33,025
33,862
27,817
50,974
56,664
52,800
136,567
172,464
191,597
326,635
355,338
679,581
341,101
348,736
346,818
346,033
255,484
255,826
257,723
223,454
207,736
205,808
209,571
200,205
200,205209,571205,808207,736223,454257,723255,826255,484346,033346,818348,736341,101679,581355,338326,635191,597172,464136,56752,80056,66450,97427,81733,86233,02534,04516,81616,09016,943321,453161,280133,80417,72719,11919,96420,00020,16921,32021,30021,79122,87022,63221,15622,45423,06923,95821,09622,20321,33720,36720,23417,52114,79312,968000
       Property Plant Equipment 
0
0
0
10,528
12,353
15,081
17,741
17,874
18,829
19,695
18,558
21,404
20,516
19,901
18,586
20,062
20,225
19,146
18,623
18,628
17,536
17,367
17,316
16,453
15,061
15,193
14,176
13,643
14,238
13,385
14,087
16,112
15,557
15,453
15,393
15,630
20,676
17,127
94,930
125,340
143,654
230,909
226,281
200,379
210,557
225,446
220,272
221,448
187,175
185,781
182,219
165,488
160,237
157,251
154,042
149,852
149,852154,042157,251160,237165,488182,219185,781187,175221,448220,272225,446210,557200,379226,281230,909143,654125,34094,93017,12720,67615,63015,39315,45315,55716,11214,08713,38514,23813,64314,17615,19315,06116,45317,31617,36717,53618,62818,62319,14620,22520,06218,58619,90120,51621,40418,55819,69518,82917,87417,74115,08112,35310,528000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,312
9,015
9,589
9,662
32,582
33,208
32,852
34,342
35,632
36,450
34,581
33,007
94,561
33,898
33,427
34,682
26,907
29,736
0
0
0
0
0
0
0
000000029,73626,90734,68233,42733,89894,56133,00734,58136,45035,63234,34232,85233,20832,5829,6629,5899,0159,3120000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,480
0
0
0
0
0
0
0
53,790
0
0
0
0
0
0
0
12,255
12,255000000053,79000000002,480000000000000000000000000000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,729
8,621
8,453
8,820
2,762
2,762
2,780
2,821
7,295
9,012
9,013
20,504
20,896
39,405
38,621
-1
37,154
43,888
36,042
28,949
32,195
20,122
-1
0
0
0
000-120,12232,19528,94936,04243,88837,154-138,62139,40520,89620,5049,0139,0127,2952,8212,7802,7622,7628,8208,4538,6212,729000000000000000000000000000000
> Total Liabilities 
0
0
0
43,442
39,497
51,879
37,871
28,084
40,766
21,928
27,421
29,968
28,407
36,688
23,935
30,772
36,671
33,742
41,553
343,928
360,060
353,779
376,316
382,457
356,313
369,935
352,076
416,432
221,518
199,542
189,650
208,770
183,434
205,893
282,304
113,516
266,228
262,621
304,401
356,841
346,203
471,852
469,140
747,521
507,080
537,437
474,953
1,139,826
1,127,685
751,607
725,168
723,895
667,268
322,243
358,709
387,154
387,154358,709322,243667,268723,895725,168751,6071,127,6851,139,826474,953537,437507,080747,521469,140471,852346,203356,841304,401262,621266,228113,516282,304205,893183,434208,770189,650199,542221,518416,432352,076369,935356,313382,457376,316353,779360,060343,92841,55333,74236,67130,77223,93536,68828,40729,96827,42121,92840,76628,08437,87151,87939,49743,442000
   > Total Current Liabilities 
0
0
0
43,442
39,497
51,879
37,871
28,084
40,766
21,928
27,421
29,968
28,407
36,688
23,935
30,772
36,671
33,742
41,553
76,758
56,374
57,664
48,083
69,506
54,382
72,818
51,931
87,554
94,989
57,145
64,275
75,784
52,574
62,458
282,304
113,516
266,228
262,621
304,401
195,134
187,654
287,948
293,496
577,733
352,931
375,597
310,696
334,317
330,165
261,583
225,927
195,491
150,485
201,111
257,624
284,579
284,579257,624201,111150,485195,491225,927261,583330,165334,317310,696375,597352,931577,733293,496287,948187,654195,134304,401262,621266,228113,516282,30462,45852,57475,78464,27557,14594,98987,55451,93172,81854,38269,50648,08357,66456,37476,75841,55333,74236,67130,77223,93536,68828,40729,96827,42121,92840,76628,08437,87151,87939,49743,442000
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,000
5,000
5,000
5,000
43,927
0
14,100
12,000
3,365
34,959
3,653
16,522
2,748
3,286
143,435
0
0
5,948
3,336
68,490
7,692
9,973
14,289
14,218
11,392
14,446
15,006
15,527
14,897
13,217
13,826
14,905
14,729
14,827
14,787
0
0
0014,78714,82714,72914,90513,82613,21714,89715,52715,00614,44611,39214,21814,2899,9737,69268,4903,3365,94800143,4353,2862,74816,5223,65334,9593,36512,00014,100043,9275,0005,0005,0005,0000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
16,522
2,748
3,286
143,435
0
0
5,948
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000005,94800143,4353,2862,74816,522000000000000000000000000000000
       Accounts payable 
0
0
0
10,668
8,160
7,644
9,401
8,592
10,498
8,410
8,288
9,831
7,696
16,317
7,356
13,376
8,276
9,733
9,335
18,487
16,850
16,278
15,064
21,676
14,232
18,682
14,437
19,739
22,211
23,200
25,919
29,428
17,405
29,636
24,511
32,652
29,371
44,600
30,081
57,533
41,737
67,592
61,703
59,307
46,676
76,222
54,908
64,558
42,420
34,833
36,158
180,762
135,658
186,324
242,652
267,924
267,924242,652186,324135,658180,76236,15834,83342,42064,55854,90876,22246,67659,30761,70367,59241,73757,53330,08144,60029,37132,65224,51129,63617,40529,42825,91923,20022,21119,73914,43718,68214,23221,67615,06416,27816,85018,4879,3359,7338,27613,3767,35616,3177,6969,8318,2888,41010,4988,5929,4017,6448,16010,668000
       Other Current Liabilities 
0
0
0
32,774
31,337
44,235
28,470
10,208
27,771
13,518
19,133
15,065
17,201
17,667
13,907
15,067
25,723
21,337
26,067
38,888
20,120
27,956
20,634
1,812
38,087
40,036
25,494
64,450
37,819
30,292
21,834
43,608
31,883
32,822
257,793
80,864
53,594
55,632
55,042
73,658
75,786
153,617
158,986
453,852
221,397
211,793
178,860
201,829
220,014
212,924
174,864
0
0
0
0
0
00000174,864212,924220,014201,829178,860211,793221,397453,852158,986153,61775,78673,65855,04255,63253,59480,864257,79332,82231,88343,60821,83430,29237,81964,45025,49440,03638,0871,81220,63427,95620,12038,88826,06721,33725,72315,06713,90717,66717,20115,06519,13313,51827,77110,20828,47044,23531,33732,774000
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
267,170
303,686
296,115
328,233
312,951
301,931
297,117
300,145
328,878
126,529
142,397
125,375
132,986
130,860
143,435
0
0
0
0
0
161,707
158,549
183,904
175,644
169,788
154,149
161,840
164,257
805,509
797,520
490,024
499,241
528,404
516,783
121,132
101,085
102,575
102,575101,085121,132516,783528,404499,241490,024797,520805,509164,257161,840154,149169,788175,644183,904158,549161,70700000143,435130,860132,986125,375142,397126,529328,878300,145297,117301,931312,951328,233296,115303,686267,1700000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
83,639
67,315
61,308
56,354
61,331
39,881
33,073
37,752
32,977
20,540
18,426
18,426
19,058
0
0
0
0
000019,05818,42618,42620,54032,97737,75233,07339,88161,33156,35461,30867,31583,639000000000000000000000000000000000000000
> Total Stockholder Equity
0
0
0
407,108
369,322
461,538
447,263
441,397
512,595
536,788
536,664
491,015
442,554
396,028
361,899
316,141
344,991
299,355
316,220
252,828
209,175
163,042
159,425
252,231
178,636
107,520
217,630
278,194
252,686
181,527
638,977
528,468
437,063
316,237
1,240,766
1,116,281
1,084,291
966,778
1,409,193
1,242,673
1,215,392
1,799,922
1,590,003
1,177,089
1,662,746
1,386,736
1,185,746
927,803
709,698
504,947
366,440
815,911
673,239
1,727,435
1,816,796
1,592,839
1,592,8391,816,7961,727,435673,239815,911366,440504,947709,698927,8031,185,7461,386,7361,662,7461,177,0891,590,0031,799,9221,215,3921,242,6731,409,193966,7781,084,2911,116,2811,240,766316,237437,063528,468638,977181,527252,686278,194217,630107,520178,636252,231159,425163,042209,175252,828316,220299,355344,991316,141361,899396,028442,554491,015536,664536,788512,595441,397447,263461,538369,322407,108000
   Common Stock
0
0
0
22,871
22,871
22,871
22,871
23,193
23,193
23,193
23,193
23,193
23,193
23,193
23,193
23,193
23,193
23,193
23,193
23,193
23,314
23,518
24,052
24,353
24,399
24,534
26,062
26,142
26,152
26,187
30,749
30,751
30,751
30,751
30,759
30,787
31,662
31,815
35,865
36,055
36,888
39,734
39,779
39,800
43,428
43,542
43,582
43,634
43,634
46,527
46,538
51,702
52,003
58,642
0
0
0058,64252,00351,70246,53846,52743,63443,63443,58243,54243,42839,80039,77939,73436,88836,05535,86531,81531,66230,78730,75930,75130,75130,75130,74926,18726,15226,14226,06224,53424,39924,35324,05223,51823,31423,19323,19323,19323,19323,19323,19323,19323,19323,19323,19323,19323,19323,19322,87122,87122,87122,871000
   Retained Earnings Total Equity00000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-27
-328
2,405
0
11,725
11,080
12,771
14,155
16,181
0
0
0
0
0
0
0
000000016,18114,15512,77111,08011,72502,405-328-270000000000000000000000000000000000000000
   Capital Surplus 00000000000000000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,441,263
1,442,072
1,464,553
1,959,705
1,959,199
1,959,199
1,980,293
1,981,033
1,979,493
2,052,124
2,071,584
2,623,178
2,650,142
2,801,571
3,441,647
3,457,526
3,452,850
4,140,030
4,161,367
4,157,533
4,178,416
4,181,130
19,042
18,531
764,209
18,402
18,376
0
0
0018,37618,402764,20918,53119,0424,181,1304,178,4164,157,5334,161,3674,140,0303,452,8503,457,5263,441,6472,801,5712,650,1422,623,1782,071,5842,052,1241,979,4931,981,0331,980,2931,959,1991,959,1991,959,7051,464,5531,442,0721,441,263000000000000000000000000000



Balance Sheet

Currency in DKK. All numbers in thousands.




Cash Flow

Currency in DKK. All numbers in thousands.




Income Statement

Currency in DKK. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue342,788
Cost of Revenue-19,174
Gross Profit323,614323,614
 
Operating Income (+$)
Gross Profit323,614
Operating Expense-920,005
Operating Income-577,217-596,391
 
Operating Expense (+$)
Research Development684,902
Selling General Administrative89,849
Selling And Marketing Expenses0
Operating Expense920,005774,751
 
Net Interest Income (+$)
Interest Income45,324
Interest Expense-24,888
Other Finance Cost-4,093
Net Interest Income16,343
 
Pretax Income (+$)
Operating Income-577,217
Net Interest Income16,343
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-708,865-577,217
EBIT - interestExpense = -24,888
-703,739
-678,851
Interest Expense24,888
Earnings Before Interest and Taxes (EBIT)0-683,977
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-708,865
Tax Provision--5,126
Net Income From Continuing Ops-703,739-703,739
Net Income-703,739
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0-16,343
 

Technical Analysis of Zealand Pharma A/S
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Zealand Pharma A/S. The general trend of Zealand Pharma A/S is BULLISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Zealand Pharma A/S's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (85.7%) Bearish trend (-85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Zealand Pharma A/S.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 731.00 < 749.00.

The bearish price targets are: 660.00 > 505.50 > 502.00.

Tweet this
Zealand Pharma A/S Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Zealand Pharma A/S. The current mas is .

The long score for the Moving Averages is 13/14.
The longshort score for the Moving Averages is 12/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Zealand Pharma A/S Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Zealand Pharma A/S. The current macd is 37.82.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Zealand Pharma A/S price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Zealand Pharma A/S. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Zealand Pharma A/S price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Zealand Pharma A/S Daily Moving Average Convergence/Divergence (MACD) ChartZealand Pharma A/S Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Zealand Pharma A/S. The current adx is 36.99.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Zealand Pharma A/S shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Zealand Pharma A/S Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Zealand Pharma A/S. The current sar is 743.49.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Zealand Pharma A/S Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Zealand Pharma A/S. The current rsi is 56.50. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending down: The RSI is trending down. -1
Zealand Pharma A/S Daily Relative Strength Index (RSI) ChartZealand Pharma A/S Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Zealand Pharma A/S. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Zealand Pharma A/S price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Zealand Pharma A/S Daily Stochastic Oscillator ChartZealand Pharma A/S Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Zealand Pharma A/S. The current cci is -19.83045716.

Zealand Pharma A/S Daily Commodity Channel Index (CCI) ChartZealand Pharma A/S Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Zealand Pharma A/S. The current cmo is -0.66843012.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Zealand Pharma A/S Daily Chande Momentum Oscillator (CMO) ChartZealand Pharma A/S Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Zealand Pharma A/S. The current willr is -75.70621469.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Zealand Pharma A/S is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Zealand Pharma A/S Daily Williams %R ChartZealand Pharma A/S Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Zealand Pharma A/S.

Zealand Pharma A/S Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Zealand Pharma A/S. The current atr is 32.39.

Zealand Pharma A/S Daily Average True Range (ATR) ChartZealand Pharma A/S Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Zealand Pharma A/S. The current obv is 18,605,072.

Zealand Pharma A/S Daily On-Balance Volume (OBV) ChartZealand Pharma A/S Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Zealand Pharma A/S. The current mfi is 46.23.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Zealand Pharma A/S Daily Money Flow Index (MFI) ChartZealand Pharma A/S Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Zealand Pharma A/S.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-07CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-08STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-11-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-14STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-11-17STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-22BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-23STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-29WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-30CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-01STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-05STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-29CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-31SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-06RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-16SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-01MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-05WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-07ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-12WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-27CMO SHORT ENTRY LONG CLOSEZero line crossover to downside

6.3. Candlestick Patterns

Zealand Pharma A/S Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Zealand Pharma A/S based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5056.503
Ma 20Greater thanMa 50695.275
Ma 50Greater thanMa 100571.588
Ma 100Greater thanMa 200459.804
OpenGreater thanClose698.000
Total5/5 (100.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Zealand Pharma A/S with someone you think should read this too:
  • Are you bullish or bearish on Zealand Pharma A/S? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Zealand Pharma A/S? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Zealand Pharma A/S

I send you an email if I find something interesting about Zealand Pharma A/S.


Comments

How you think about this?

Leave a comment

Stay informed about Zealand Pharma A/S.

Receive notifications about Zealand Pharma A/S in your mailbox!